Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Silexion Therapeutics Corporation | SLXNW | NASDAQ | Equity Warrant |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.0252 | 18:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0252 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 0 | 0 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | 0.0252 | USD |
Silexion Therapeutics Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 363.58k | - | - | - | 0.04 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Silexion Therapeutics
| Date | Time | Source | Heading |
|---|---|---|---|
| 11/20/2024 | 05:15 | Edgar (US Regulatory) | Form SC 13D - General Statement of Acquisition of Beneficial.. |
| 11/19/2024 | 15:10 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 11/19/2024 | 15:08 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 11/19/2024 | 15:06 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/14/2024 | 08:03 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/14/2024 | 07:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/13/2024 | 15:05 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 11/01/2024 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/31/2024 | 16:24 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under.. |
| 10/22/2024 | 08:02 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 10/16/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 10/16/2024 | 08:32 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
SLXNW Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. |
